Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Srdan Verstovsek, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas and Oklahoma.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University at BuffaloResidency, Internal Medicine, 1995 - 1998
University of Zagreb Faculty of MedicineClass of 1992
Certifications & Licensure
TX State Medical License 1999 - 2026
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- 15 citationsSotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver
Haematologica. 2024-08-01 - Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel
American Journal of Hematology. 2024-07-01 - 3 citationsA randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase...Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, Alessandro Isidori, Peter Te Boekhorst
Haematologica. 2024-06-01
Press Mentions
Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022- FDA Approves Pemigatinib to Treat Rare NeoplasmsAugust 30th, 2022
- FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 RearrangementAugust 26th, 2022
Grant Support
- Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAMLUNIVERSITY OF TX MD ANDERSON CAN CTR2020–2025
